Abolishing endometriosis inflammation
Endometriosis, a disease that causes severe pain and infertility, and is difficult to treat, partially runs in families. It is a very prevalent condition that affects approximately 10% of women of reproductive age, around 190 million globally.
At the moment, endometriosis treatment relies on painkillers, surgery or hormonal treatments, which shut down the menstrual cycle altogether and therefore, are not an option if women want to have children.
A collaborative study between the University of Oxford, University of Queensland, Baylor College of Medicine, University of Wisconsin-Madison and Bayer AG, lead by Prof Krina Zondervan and Dr Thomas Tapmeier, now at Monash, has identified the Neuropeptide S receptor as a target which could be a potential new way of treating inflammation and pain in endometriosis, and as a non-hormonal target could allow for treatment AND the option of having children. Read the full story in The Conversation.
Dr Thomas Tapmeier, an internationally recognised researcher within the Department of Obstetrics and Gynaecology said, "We started with the 'Google-approach', scanned the whole genome searching for any gene that might come up as connected to endometriosis. Our research provides the basis for the design of new drugs to treat endometriosis-related pain and inflammation, we hope”.
"We hope that our study enables swift translation of this research into the clinic so that, e.g., anti-NPSR1 drugs become available to ease pain and suffering in endometriosis".
Thomas T. Tapmeier Nilufer Rahmioglu Jianghai Lin Bianca de Leo Maik Obendorf Muthuswamy Raveendran Oliver M. Fischer Cemsel Bafligil Manman Guo [...] Krina T. Zondervan. Neuropeptide S receptor 1 is a nonhormonal treatment target in endometriosis SCIENCE TRANSLATIONAL MEDICINE 25 Aug 2021 Vol 13, Issue 608 DOI: 10.1126/scitranslmed.abd6469
About Monash University
Monash University is Australia’s largest university with more than 80,000 students. In the 60 years since its foundation, it has developed a reputation for world-leading high-impact research, quality teaching, and inspiring innovation.
With four campuses in Australia and a presence in Malaysia, China, India, Indonesia and Italy, it is one of the most internationalised Australian universities.
As a leading international medical research university with the largest medical faculty in Australia and integration with leading Australian teaching hospitals, we consistently rank in the top 50 universities worldwide for clinical, pre-clinical and health sciences.